Literature DB >> 19286587

Immune response in human cerebral cavernous malformations.

Changbin Shi1, Robert Shenkar, Hongyan Du, Edward Duckworth, Harish Raja, H Hunt Batjer, Issam A Awad.   

Abstract

BACKGROUND AND
PURPOSE: Preliminary observations suggesting the presence of B and plasma cells and oligoclonality of immunoglobulin (Ig) G in cerebral cavernous malformations (CCM) have motivated a systematic study correlating the infiltration of the immune cells with clinical activity and antigen-triggered immune response in surgically excised lesions.
METHODS: Infiltration of plasma, B, T, and human leukocyte antigen-DR-expressing cells and macrophages within 23 excised CCM was related to clinical activity. Relative amounts of Ig isotypes were determined. IgG clonality of mRNA from CCM was assessed by spectratyping, cloning, and sequencing.
RESULTS: Infiltration of the immune cells ranged widely within CCM lesions, and cells were generally coexpressed with each other. Immune cell infiltration did not associate with recent bleeding and lesion growth. Significantly more B lymphocytes in CCM lesions were associated with venous anomaly. More T cells were present in solitary lesions. More T cells and less macrophages were present in CCM from younger subjects. IgG isotype was present in all CCM lesions. Most lesions also expressed IgM and IgA, with IgM predominance over IgA correlating with recent CCM growth. Oligoclonality was shown in IgG mRNA from CCM, but not from peripheral blood lymphocytes, with only 8 complementary-determining region 3 sequences observed among 134 clones from 2 CCM lesions.
CONCLUSIONS: An antigen-directed oligoclonal IgG immune response is present within CCM lesions regardless of recent clinical activity. Apparent differences in immune response in younger patients and in lesions with recent growth will need confirmation in other series. The pathogenicity of oligoclonal immune response will require systematic hypothesis testing in recently available CCM murine models.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19286587      PMCID: PMC2792996          DOI: 10.1161/STROKEAHA.108.538769

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  37 in total

Review 1.  Statistical analysis of CDR3 length distributions for the assessment of T and B cell repertoire biases.

Authors:  Patrick Miqueu; Marina Guillet; Nicolas Degauque; Jean-Christophe Doré; Jean-Paul Soulillou; Sophie Brouard
Journal:  Mol Immunol       Date:  2006-08-22       Impact factor: 4.407

2.  Intracerebral hemorrhage-induced brain injury is aggravated in senescence-accelerated prone mice.

Authors:  Jae-Chul Lee; Geum-Sil Cho; Byung-Ok Choi; Hyoung Chun Kim; Yong-Sun Kim; Won-Ki Kim
Journal:  Stroke       Date:  2005-12-01       Impact factor: 7.914

Review 3.  Cerebral cavernous malformation: new molecular and clinical insights.

Authors:  N Revencu; M Vikkula
Journal:  J Med Genet       Date:  2006-03-29       Impact factor: 6.318

4.  Predominant VH genes expressed in innate antibodies are associated with distinctive antigen-binding sites.

Authors:  K J Seidl; J A Wilshire; J D MacKenzie; A B Kantor; L A Herzenberg; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

5.  B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions.

Authors:  S E Baranzini; M C Jeong; C Butunoi; R S Murray; C C Bernard; J R Oksenberg
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

6.  Variations in structural protein expression and endothelial cell proliferation in relation to clinical manifestations of cerebral cavernous malformations.

Authors:  Robert Shenkar; Hemant Sarin; Nabil A Awadallah; Judith Gault; Bette K Kleinschmidt-DeMasters; Issam A Awad
Journal:  Neurosurgery       Date:  2005-02       Impact factor: 4.654

7.  Cerebral venous malformations have distinct genetic origin from cerebral cavernous malformations.

Authors:  Bulent Guclu; Ali K Ozturk; Katie L Pricola; Askin Seker; Memet Ozek; Murat Gunel
Journal:  Stroke       Date:  2005-10-20       Impact factor: 7.914

8.  Detection of antigen in bronchial epithelium and macrophages in acute Kawasaki disease by use of synthetic antibody.

Authors:  Anne H Rowley; Susan C Baker; Stanford T Shulman; Francesca L Garcia; Judith A Guzman-Cottrill; Pauline Chou; Masaru Terai; Tomisaku Kawasaki; Mitra B Kalelkar; Susan E Crawford
Journal:  J Infect Dis       Date:  2004-07-16       Impact factor: 5.226

9.  Ccm1 is required for arterial morphogenesis: implications for the etiology of human cavernous malformations.

Authors:  Kevin J Whitehead; Nicholas W Plummer; Jennifer A Adams; Douglas A Marchuk; Dean Y Li
Journal:  Development       Date:  2004-03       Impact factor: 6.868

10.  Neuronal expression of the Ccm2 gene in a new mouse model of cerebral cavernous malformations.

Authors:  Nicholas W Plummer; Teresa L Squire; Sudha Srinivasan; Elizabeth Huang; Jon S Zawistowski; Hiroaki Matsunami; Laura P Hale; Douglas A Marchuk
Journal:  Mamm Genome       Date:  2006-02-07       Impact factor: 2.957

View more
  23 in total

Review 1.  Cavernous angiomas: deconstructing a neurosurgical disease.

Authors:  Issam A Awad; Sean P Polster
Journal:  J Neurosurg       Date:  2019-07-01       Impact factor: 5.115

Review 2.  Cavernous malformations: natural history, diagnosis and treatment.

Authors:  Sachin Batra; Doris Lin; Pablo F Recinos; Jun Zhang; Daniele Rigamonti
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

3.  Distinctive distribution of lymphocytes in unruptured and previously untreated brain arteriovenous malformation.

Authors:  Yi Guo; Tarik Tihan; Helen Kim; Christopher Hess; Michael T Lawton; William L Young; Yuanli Zhao; Hua Su
Journal:  Neuroimmunol Neuroinflamm       Date:  2014

4.  B-Cell Depletion Reduces the Maturation of Cerebral Cavernous Malformations in Murine Models.

Authors:  Changbin Shi; Robert Shenkar; Hussein A Zeineddine; Romuald Girard; Maged D Fam; Cecilia Austin; Thomas Moore; Rhonda Lightle; Lingjiao Zhang; Meijing Wu; Ying Cao; Murat Gunel; Angeliki Louvi; Autumn Rorrer; Carol Gallione; Douglas A Marchuk; Issam A Awad
Journal:  J Neuroimmune Pharmacol       Date:  2016-04-16       Impact factor: 4.147

Review 5.  STRIPAK complexes: structure, biological function, and involvement in human diseases.

Authors:  Juyeon Hwang; David C Pallas
Journal:  Int J Biochem Cell Biol       Date:  2013-12-11       Impact factor: 5.085

6.  Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease.

Authors:  Romuald Girard; Omaditya Khanna; Robert Shenkar; Lingjiao Zhang; Meijing Wu; Michael Jesselson; Hussein A Zeineddine; Anupriya Gangal; Maged D Fam; Christopher C Gibson; Kevin J Whitehead; Dean Y Li; James K Liao; Changbin Shi; Issam A Awad
Journal:  Biomark Med       Date:  2016-02-09       Impact factor: 2.851

7.  Management of brainstem cavernous malformations.

Authors:  Tarek Y El Ahmadieh; Salah G Aoun; Bernard R Bendok; H Hunt Batjer
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-06

8.  Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity.

Authors:  Rebecca A Stockton; Robert Shenkar; Issam A Awad; Mark H Ginsberg
Journal:  J Exp Med       Date:  2010-03-22       Impact factor: 14.307

Review 9.  Recent insights into cerebral cavernous malformations: animal models of CCM and the human phenotype.

Authors:  Aubrey C Chan; Dean Y Li; Michel J Berg; Kevin J Whitehead
Journal:  FEBS J       Date:  2010-01-22       Impact factor: 5.542

10.  Decreased Krev interaction-trapped 1 expression leads to increased vascular permeability and modifies inflammatory responses in vivo.

Authors:  Maripat Corr; Irina Lerman; Julia M Keubel; Lisa Ronacher; Ravi Misra; Frances Lund; Ingrid H Sarelius; Angela J Glading
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-08-23       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.